ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome. These data, together with data already presented at ASHG last year, support miransertib’s further development as a potential first systemic treatment for patients suffering from overgrowth diseases, such as Proteus syndrome. The study, published in the American Journal of Human Genetics, and led by the National Institutes of Health (NIH), demonstrated good target engagement, tolerability and reductions in lesion size and pain, especially in children.